Company

From an IMIB spin-off to an international biomedical company

We bring science from the laboratory into clinical practice through functional biomarkers for precision immunology.

About us

Leading biomedical innovator

More information

Manifiesto

Viva in Vitro

More information

VIVA In Vitro Diagnostics was founded in 2021 as the first spin-off from the IMIB (Murcia Institute for Bio-Health Research), with the mission of transforming research into immunology and inflammation into solutions applicable to clinical practice and biomedical development.

Meet VIVA-ELISA®:
Innovation at the Service of Personalised Medicine

Patented technology currently undergoing development and clinical validation to measure the functional activation of NLRP3 and provide actionable information on the patient’s immune status.

Find out more under Products and Services

Acknowledgements

Recognised excellence in biomedical innovation

European Innovation Council (EIC)

The European Innovation Council (EIC) has selected Viva in Vitro Diagnostics for the EIC Transition programme, awarding us €2.5 million in non-dilutive funding to advance the development of VIVA-ELISA®.
This recognition boosts our functional NLRP3 biomarker technology, with sepsis serving as the first clinical validation.

Business Acceleration Services (BAS)

The EU has included Viva in Vitro in its Business Acceleration Services (BAS) programme, which aims to bring disruptive technologies to maturity, build robust business cases and facilitate connections with institutions, corporations, investors and private companies.

Murcia Region Entrepreneur of the Year Award 2022

Organised by the
Consejería de Economía, Hacienda y Empresa, through the Instituto de Fomento (Info).

CEI Mare Nostrum 2022 Award

Recognises Viva In Vitro’s commitment to biomedical innovation and improving healthcare.

Impact Business 2023 Initiative Award

Awarded by the Ship2B Foundation following the successful completion of its Health&Care acceleration programme.

Innovative SME Seal by ENISA

Institutional recognition of our capacity for innovation.

EIBT Seal

‘Innovative Technology-Based Company’ seal awarded by ANCES, the National Association of CEEIs.

Company of the Year Award 2023

Awarded by Banco Sabadell in recognition of our excellence in biomedical innovation./p>

Isaac Foundation Research Award 2024

2024 edition, for our groundbreaking contribution to immunological stratification in sepsis./p>

Roadmap: Key Milestones and Next Steps
2021

Foundation of VIVA In Vitro Diagnostics as a spin-off from IMIB.

2022

First round of funding: €275K. and ENISA financing for 195K €

2023
  • First round of funding: €275K.
  • ENISA funding of €195K.
2024
  • Development of the regulatory roadmap.
  • Implementation of protocols to protect trade secrets.
  • Funding round of €1.34 million.
  • Clinical validation and TRL4 validation agreements.
  • Progress on the ISO 13485 quality management system.
2025-2027
  • Development of the EIC Transition programme: €2.5 million.
  • Development of VIVA-ELISA® RUO.
  • Optimisation of VIVA-ELISA® for clinical use.
  • A multicentre clinical trial for translational validation in sepsis as the primary indication.
  • Regulatory progress prioritising CE marking under the IVDR and the ISO 13485 quality management system.
  • Manufacturing plan, expansion into new therapeutic areas and optimisation of clinical data.
  • Outreach programme and commercialisation roadmap.
2028-2029
  • Preparation for the commercial launch of VIVA-ELISA® and development of scalable solutions for clinical laboratories..
See full Roadmap.
Under clinical and translational validation

Our network of collaborations with leading hospitals and research centres, including Vall d’Hebron, the University Clinical Hospital of Valencia, Santa Lucía Hospital in Cartagena, Virgen de la Arrixaca Hospital, Virgen de la Victoria Hospital in Málaga and Jerez Hospital, enables us to progress with a multicentre clinical trial for the translational validation of NLRP3 functional biomarkers.
This study, which has already enrolled 200 patients and is expected to reach 360, involves the analysis of more than 100 variables to generate key information on early prognosis, immunological stratification and personalised medicine in sepsis, as its primary clinical indication.

More information
News
See all news
About us: a leading biomedical innovator

We are a biomedical company specialising in functional immunological information, selected by the European Commission’s European Innovation Council as one of the European projects with high potential.

Our company is underpinned by a solid scientific foundation, technological protection and financial backing, driven by national and international programmes that validate our capacity for growth in the biomedical sector.

With a multidisciplinary team combining expertise in immunology, biotechnology, biomedical engineering, clinical development and business management, we are working to transform the functional activation of NLRP3 into actionable insights for personalised medicine.

We are a strong and effective partner at the cutting edge of biomedical research.
Discover our team and collaborators
OUR COMMITMENT TO LIFE
Mission

We develop reliable and user-friendly tools to measure the functional activation of the NLRP3 inflammasome and provide actionable insights into a patient’s immune status.

Our first clinical validation focuses on sepsis, where early stratification can help identify critically ill patients, anticipate risk and support more accurate clinical decisions in the ICU and A&E.

Vision

We aim to lead the way in a new generation of solutions based on precision immunology, transforming functional immunological information into a key tool for personalised medicine and therapeutic development.

We are starting with sepsis and moving on to other inflammatory and immune-mediated diseases, such as cardiovascular, renal, neurodegenerative, autoimmune and oncological conditions.

In this way, we fulfil our commitment to patients, healthcare professionals, healthcare systems, biomedical partners and shareholders: to improve decision-making, reduce suffering and contribute to better clinical outcomes.

Our values

• EXCELLENCE: We use cutting-edge science and rigorous development, validation and management tools to translate the functional activation of NLRP3 into information that is useful for medical practice.

• RIGOUR AND PRECISION: We provide specific, actionable and validated immunological information from a scientific, clinical and regulatory perspective.

• INTEGRATION AND IMPACT: We design solutions that are compatible with healthcare workflows and useful for hospitals, biomedical research and personalised medicine programmes.

  • 2021
    Foundation of VIVA In Vitro Diagnostics as a spin-off from IMIB.
  • 2022
    First round of funding: €275K.
    ENISA funding of €195K.
  • 2023
    -Second round of funding (€880K + Neotec €250K + INFO EPTE €44K).
    -Establishment of headquarters and consolidation of the key team.
  • 2024
    – Development of the regulatory roadmap.
    – Implementation of protocols to protect trade secrets.
    – Funding round €1,34M.
    – Clinical validation and TRL4 validation agreements.
    – Progress on the ISO 13485 quality management system.
  • 2025-2027
    – Development of the EIC Transition programme: €2.5 million.
    – Development of VIVA-ELISA® RUO.
    – Optimisation of VIVA-ELISA® for clinical use.
    – A multicentre clinical trial for translational validation in sepsis as the primary indication.
    – Regulatory progress prioritising CE marking under the IVDR and the ISO 13485 quality management system.
    – Manufacturing plan, expansion into new therapeutic areas and optimisation of clinical data.
    – Outreach programme and commercialisation roadmap.
  • 2028-2029
    Preparation for the commercial launch of VIVA-ELISA® and development of scalable solutions for clinical laboratories.
  • 2021
    Foundation of VIVA In Vitro Diagnostics as a spin-off from IMIB.
  • 2022
    First round of funding: €275K.
    ENISA funding of €195K.
  • 2023
    -Second round of funding (€880K + Neotec €250K + INFO EPTE €44K).
    -Establishment of headquarters and consolidation of the key team.
  • 2024
    – Development of the regulatory roadmap.
    – Implementation of protocols to protect trade secrets.
    – Funding round €1,34M.
    – Clinical validation and TRL4 validation agreements.
    – Progress on the ISO 13485 quality management system.
  • 2025-2027
    – Development of the EIC Transition programme: €2.5 million.
    – Development of VIVA-ELISA® RUO.
    – Optimisation of VIVA-ELISA® for clinical use.
    – A multicentre clinical trial for translational validation in sepsis as the primary indication.
    – Regulatory progress prioritising CE marking under the IVDR and the ISO 13485 quality management system.
    – Manufacturing plan, expansion into new therapeutic areas and optimisation of clinical data.
    – Outreach programme and commercialisation roadmap.
  • 2028-2029
    Preparation for the commercial launch of VIVA-ELISA® and development of scalable solutions for clinical laboratories.